Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
March 27, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

- Announces key appointments in oncology R&D and business development functions - Cash and cash equivalents of $283 million expected to provide runway into 2026 FOSTER CITY, Calif., March ...
March 27, 2023 08:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
March 02, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences

Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical...
February 02, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
January 12, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
January 05, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

Plans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases Expects to initiate proof of concept trials in CML and obesity and to report top-line data from DUET,...
December 23, 2022 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

FOSTER CITY, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
December 20, 2022 19:40 ET | Source: Terns Pharmaceuticals, Inc.

Terns Announces Pricing of $75 Million Public Offering

FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
December 20, 2022 08:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...